Novartis partners with Phase 4 Partners and other investors to create Mereo BioPharma
Novartis announced a swap of clinical assets for equity with Mereo BioPharma Group The deal involves compounds in areas of unmet medical need including BPS-804, to improve bone density in brittle bone syndrome, an orphan disease; BCT-197 for acute exacerbations in COPD, and BGS-649 for obese men. July 29, 2015